Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Rapid HIV Testing Program in the Emergency Department

This study has been completed.
Sponsor:
Collaborator:
Gilead Sciences
Information provided by:
Temple University
ClinicalTrials.gov Identifier:
NCT00548041
First received: October 19, 2007
Last updated: March 16, 2009
Last verified: March 2009
History of Changes
  Purpose

The purpose of the study is to evaluate the feasibility of a rapid HIV testing program in the Temple University Hospital(TUH)Emergency Department. We hypothesize that a rapid HIV testing program in the TUH Emergency Department is feasible. Patients presenting to the Adult TUH Emergency Department with certain conditions will be offered rapid HIV testing. Testing will be performed by oral swab using the OraQuick Advance test. Patients will receive post-test counseling.


Condition Intervention
HIV Infections
 Other: HIV test by oral swab

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Pilot Study to Evaluate a Rapid HIV Testing Program in the Emergency Department

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by Temple University:
  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

One of the following conditions:

  • Sexually transmitted disease evaluation or prior history of sexually transmitted disease
  • Pregnancy
  • Clinical condition that suggests possible immunodeficiency
  • History of illicit drug use
  • History of chronic viral hepatitis
  • Patients with unexplained pneumonia or recurrent pneumonia
  • Male patients who have a history of sex with men
  • Abdominal pain in a sexually active woman or urethritis in a man
  • Trauma.
  • Age 18 years old or older.

Exclusion Criteria:

  • Age less than 18 years.
  • None of the above conditions.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00548041

Locations
United States, Pennsylvania
Temple University Hospital
Philadelphia, Pennsylvania, United States, 19140
Sponsors and Collaborators
Temple University
Gilead Sciences
Investigators
Principal Investigator: Ellen Tedaldi, M.D. Temple University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00548041     History of Changes
Other Study ID Numbers: 11007
Study First Received: October 19, 2007
Last Updated: March 16, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Temple University:
HIV
Emergency Department
HIV Seronegativity

ClinicalTrials.gov processed this record on March 03, 2015